Works matching DE "INCRETINS"
Results: 673
Uso de las terapias basadas en incretinas y estrategias educativas: un análisis desde los cuatro principios bioéticos.
- Published in:
- Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2024, v. 11, p. 30, doi. 10.24875/RME.M24000040
- By:
- Publication type:
- Article
Hormonal Regulation in the Obese Population.
- Published in:
- Nutritional Perspectives: Journal of the Council on Nutrition, 2024, v. 47, n. 4, p. 16
- By:
- Publication type:
- Article
Psychopharmakainduzierte Gewichtszunahme – sind Inkretine/Twinkretine eine Option?
- Published in:
- Der Nervenarzt, 2025, v. 96, n. 1, p. 93, doi. 10.1007/s00115-024-01788-1
- By:
- Publication type:
- Article
Pathophysiology.
- Published in:
- Current Medical Literature: Diabetes, 2012, v. 29, n. 3, p. 79
- Publication type:
- Article
Tirzepatide a novel anti diabetic molecule unfold dual action.
- Published in:
- Discover Public Health, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12982-024-00200-2
- By:
- Publication type:
- Article
Testosterone, incretins and improving cardiometabolic health: An endocrinologist's perspective.
- Published in:
- Medicine Today, 2024, v. 25, n. 6, p. 21
- By:
- Publication type:
- Article
Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response.
- Published in:
- European Journal of Sport Science, 2022, v. 22, n. 3, p. 381, doi. 10.1080/17461391.2021.1877830
- By:
- Publication type:
- Article
News in brief: Highlights of the American Diabetes Association 82<sup>nd</sup> Scientific Sessions.
- Published in:
- Diabetes & Primary Care, 2022, v. 24, n. 3, p. 85
- Publication type:
- Article
Lipid management -- Part 1: Measuring lipids and lipid targets.
- Published in:
- Diabetes & Primary Care, 2022, v. 24, n. 2, p. 41
- By:
- Publication type:
- Article
Hyperglycaemia in type 2 diabetes: Newer blood glucose-lowering therapies.
- Published in:
- Diabetes & Primary Care, 2015, v. 17, n. 6, p. 302
- By:
- Publication type:
- Article
Incretin-based therapies: Emerging evidence.
- Published in:
- 2013
- By:
- Publication type:
- Editorial
Incretin-based diabetes therapies: Updated statement from the PCDS Committee.
- Published in:
- Diabetes & Primary Care, 2013, v. 15, n. 4, p. 180
- By:
- Publication type:
- Article
The involvement of the T1R3 receptor protein in the control of glucose metabolism in mice at different levels of glycemia.
- Published in:
- Journal of Evolutionary Biochemistry & Physiology, 2014, v. 50, n. 4, p. 334, doi. 10.1134/S0022093014040061
- By:
- Publication type:
- Article
The impact of diabetes and obesity on fertility and the potential role of gut hormones as treatment.
- Published in:
- Diabetic Medicine, 2023, v. 40, n. 12, p. 1, doi. 10.1111/dme.15230
- By:
- Publication type:
- Article
INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA)
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 10, p. 1, doi. 10.1111/dme.14913
- By:
- Publication type:
- Article
Basic and clinical science posters: Actions, metabolism and therapy.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.14556
- Publication type:
- Article
Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population‐based study.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 7, p. 1157, doi. 10.1111/dme.14267
- By:
- Publication type:
- Article
Incretin‐based drugs and risk of lung cancer among individuals with type 2 diabetes.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 5, p. 868, doi. 10.1111/dme.14287
- By:
- Publication type:
- Article
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 2, p. 194, doi. 10.1111/dme.14179
- By:
- Publication type:
- Article
Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis‐related diabetes.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 11, p. 1367, doi. 10.1111/dme.14121
- By:
- Publication type:
- Article
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti‐hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 4, p. 491, doi. 10.1111/dme.13835
- By:
- Publication type:
- Article
Clinical care and other categories posters: Incretin therapies.
- Published in:
- 2019
- Publication type:
- Abstract
Clinical care and other categories posters: Incretin therapies.
- Published in:
- 2018
- Publication type:
- Abstract
Reducing the burden of diabetes complications.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 1, p. 7, doi. 10.1111/dme.13549
- By:
- Publication type:
- Article
RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 1, p. 33, doi. 10.1111/dme.13522
- By:
- Publication type:
- Article
Clinical care and other categories posters: hypoglycaemia.
- Published in:
- Diabetic Medicine, 2017, v. 34, p. 141, doi. 10.1111/dme.28_13304
- Publication type:
- Article
Clinical care and other categories posters: incretin therapies.
- Published in:
- Diabetic Medicine, 2017, v. 34, p. 144, doi. 10.1111/dme.29_13304
- Publication type:
- Article
Sitagliptin plus pantoprazole can restore but not maintain insulin independence after clinical islet transplantation: results of a pilot study.
- Published in:
- Diabetic Medicine, 2017, v. 34, n. 2, p. 204, doi. 10.1111/dme.13131
- By:
- Publication type:
- Article
Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
- Published in:
- Diabetic Medicine, 2016, v. 33, n. 7, p. 864, doi. 10.1111/dme.13021
- By:
- Publication type:
- Article
Clinical care and other categories posters: incretin therapies.
- Published in:
- Diabetic Medicine, 2016, v. 33, p. 145, doi. 10.1111/dme.36_13048
- Publication type:
- Article
Basic and clinical science posters: vascular and endothelial function.
- Published in:
- Diabetic Medicine, 2016, v. 33, p. 86, doi. 10.1111/dme.22_13048
- Publication type:
- Article
Abstracts of the Case Reports (online only).
- Published in:
- Diabetic Medicine, 2014, v. 31, n. 3, p. 379, doi. 10.1111/dme.12399
- Publication type:
- Article
HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response.
- Published in:
- Diabetic Medicine, 2014, v. 31, n. 3, p. e11, doi. 10.1111/dme.12369
- By:
- Publication type:
- Article
The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis-what happens next? A personal viewpoint.
- Published in:
- Diabetic Medicine, 2013, v. 30, n. 12, p. 1510, doi. 10.1111/dme.12336
- By:
- Publication type:
- Article
Incretins and pancreatitis-what happens next? A personal viewpoint.
- Published in:
- Diabetic Medicine, 2013, v. 30, n. 10, p. 1156, doi. 10.1111/dme.12300
- By:
- Publication type:
- Article
Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.
- Published in:
- Diabetic Medicine, 2013, v. 30, n. 10, p. 1214, doi. 10.1111/dme.12231
- By:
- Publication type:
- Article
Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2021, v. 46, n. 1, p. 28, doi. 10.1111/jcpt.13270
- By:
- Publication type:
- Article
Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2016, v. 41, n. 2, p. 116, doi. 10.1111/jcpt.12373
- By:
- Publication type:
- Article
A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2013, v. 38, n. 3, p. 181, doi. 10.1111/jcpt.12040
- By:
- Publication type:
- Article
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2012, v. 37, n. 5, p. 510, doi. 10.1111/j.1365-2710.2012.01342.x
- By:
- Publication type:
- Article
Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2012, v. 37, n. 3, p. 254, doi. 10.1111/j.1365-2710.2011.01302.x
- By:
- Publication type:
- Article
The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2012, v. 36, n. 4, p. 379, doi. 10.1111/j.1365-2036.2012.05198.x
- By:
- Publication type:
- Article
Integrating insulin secretion and ER stress in pancreatic ?-cells.
- Published in:
- Nature Cell Biology, 2012, v. 14, n. 10, p. 979, doi. 10.1038/ncb2594
- By:
- Publication type:
- Article
Tirzepatide: A Review in Type 2 Diabetes.
- Published in:
- Drugs, 2024, v. 84, n. 2, p. 227, doi. 10.1007/s40265-023-01992-4
- By:
- Publication type:
- Article
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management.
- Published in:
- Drugs, 2023, v. 83, n. 12, p. 1077, doi. 10.1007/s40265-023-01913-5
- By:
- Publication type:
- Article
Tirzepatide: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1213, doi. 10.1007/s40265-022-01746-8
- By:
- Publication type:
- Article
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 2133, doi. 10.1007/s13300-018-0483-4
- By:
- Publication type:
- Article
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 1, p. 363, doi. 10.1007/s13300-017-0338-4
- By:
- Publication type:
- Article
Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.
- Published in:
- Diabetes Therapy, 2016, v. 7, n. 4, p. 725, doi. 10.1007/s13300-016-0198-3
- By:
- Publication type:
- Article
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
- Published in:
- Diabetes Therapy, 2016, v. 7, n. 2, p. 175, doi. 10.1007/s13300-016-0165-z
- By:
- Publication type:
- Article